Effect of remimazolam versus propofol anesthesia on postoperative delirium in neurovascular surgery: study protocol for a randomized controlled, non-inferiority trial

Jeayoun Kim,Seungwon Lee,Boram Park,Woo Seog Sim,Hyun Joo Ahn,Mi-Hye Park and Ji Seon Jeong
DOI: https://doi.org/10.1186/s13741-024-00415-6
2024-06-14
Perioperative Medicine
Abstract:Remimazolam is a short-acting benzodiazepine newly approved for the induction and maintenance of general anesthesia. Remimazolam emerges as an ideal drug for the neurosurgical population due to its rapid emergence, enabling early neurological assessment, and its ability to maintain perfusion pressure, which is crucial for preventing cerebral ischemia. However, the use of benzodiazepine has been associated with an increased risk of postoperative delirium (POD). There is currently limited evidence about the relationship between remimazolam-based total intravenous anesthesia (TIVA) and POD.
surgery,anesthesiology
What problem does this paper attempt to address?
The paper attempts to address the issue of the impact of general anesthesia with remimazolam compared to general anesthesia with propofol on the incidence of postoperative delirium (POD) in neurovascular surgery. Specifically, the researchers hypothesize that in patients undergoing neurovascular surgery, the use of remimazolam for general anesthesia will not be inferior to propofol anesthesia in terms of the incidence of POD. Through this randomized controlled, non-inferiority trial, the study aims to provide evidence to support the selection of the optimal anesthetic drug to minimize the risk of POD in neurosurgical patients.